Clinical trial Recruiting at 1 site Interventional Ages 18 to 25

Community-led, family-centered communication for Hispanic childhood cancer survivors

Official title: COMUNICAR: Community-Led Family-Centered Communication for Cancer Survivorship Care

Run by Stanford University · NCT07606443 · Data updated 2026-11-12

This study tests a family-focused communication approach to help young Hispanic adult survivors, their families, and clinicians talk more effectively about survivorship care.

More Childhood Cancer trials

Quick facts

Study typeInterventional
Ages18 Years to 25 Years
SexAll
Enrollment18 (estimated)
SponsorStanford University
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Palo Alto, California)
StatusRecruiting
StartedSeptember 10, 2026
Main results expectedJuly 2028
Study endsJuly 2028
Registry record updatedNovember 4, 2026
Trial IDNCT07606443 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Hispanic/Latino survivors of childhood cancer, aged 18-25, at least 5 years post-diagnosis, receiving care at Stanford, within Jacob's Heart service area, and fluent in English or Spanish.

Probably not a fit

Individuals without current care at Stanford or outside the specified service area may not benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial will implement a family-centered communication intervention designed for Hispanic/Latino young adult survivors of childhood cancer and their support persons, in collaboration with a community organization. Participants are 18-25 years old, Hispanic/Latino, at least 5 years from diagnosis, and receiving care at Stanford, within Jacob's Heart service area. The study aims to improve dialogue among survivors, their families, and clinicians to support ongoing survivorship care. English or Spanish fluency is required, and informed consent is obtained. The intervention is conducted at Stanford with collaboration from the National Cancer Institute.

Why it matters

Potential benefit: If successful, participants may experience clearer communication and better alignment of survivorship care plans with family needs.

How similar studies have gone: Previous efforts in family-centered communication have shown promise in improving care coordination, though this exact population and community-linked model is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Childhood cancer survivor previously treated with chemotherapy and/or radiation therapy
2. Currently age 18-25 years
3. Identifies as Hispanic/Latino
4. Currently ≥5 years post cancer diagnosis
5. Fluent in English or Spanish
6. Receives medical care at Stanford
7. Lives within Jacob's Heart service area (zip codes within Monterey, Santa Cruz, Santa Clara, San Benito Counties: https://www.jacobsheart.org/service-area)
8. Ability to understand and the willingness to provide written informed consent.

Exclusion Criteria:

1\. Lack of proficiency in written and spoken English or Spanish

Where it's running

  • Stanford University
    Palo Alto, California, United States
    Recruiting

Study contacts

  • Principal investigator: Stephanie Smith, MD, MPH — Stanford University
  • Study coordinator: Stephanie Smith, MD, MPH
  • Email: smithsm@stanford.edu
  • Phone: 209-609-0208

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.